These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

812 related articles for article (PubMed ID: 33067570)

  • 1. Learning from the past: development of safe and effective COVID-19 vaccines.
    Su S; Du L; Jiang S
    Nat Rev Microbiol; 2021 Mar; 19(3):211-219. PubMed ID: 33067570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
    Arashkia A; Jalilvand S; Mohajel N; Afchangi A; Azadmanesh K; Salehi-Vaziri M; Fazlalipour M; Pouriayevali MH; Jalali T; Mousavi Nasab SD; Roohvand F; Shoja Z;
    Rev Med Virol; 2021 May; 31(3):e2183. PubMed ID: 33594794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages.
    Motamedi H; Ari MM; Dashtbin S; Fathollahi M; Hossainpour H; Alvandi A; Moradi J; Abiri R
    Int Immunopharmacol; 2021 Jul; 96():107763. PubMed ID: 34162141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
    Pushparajah D; Jimenez S; Wong S; Alattas H; Nafissi N; Slavcev RA
    Adv Drug Deliv Rev; 2021 Mar; 170():113-141. PubMed ID: 33422546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.
    Begum J; Mir NA; Dev K; Buyamayum B; Wani MY; Raza M
    Transbound Emerg Dis; 2021 May; 68(3):1111-1124. PubMed ID: 32815655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal COVID-19 vaccines: From bench to bed.
    Alu A; Chen L; Lei H; Wei Y; Tian X; Wei X
    EBioMedicine; 2022 Feb; 76():103841. PubMed ID: 35085851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?
    Al-Kassmy J; Pedersen J; Kobinger G
    Viruses; 2020 Aug; 12(8):. PubMed ID: 32784685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A systematic review of SARS-CoV-2 vaccine candidates.
    Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
    Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).
    Bennet BM; Wolf J; Laureano R; Sellers RS
    Toxicol Pathol; 2020 Oct; 48(7):800-809. PubMed ID: 32926660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Principles and Challenges in anti-COVID-19 Vaccine Development.
    Strizova Z; Smetanova J; Bartunkova J; Milota T
    Int Arch Allergy Immunol; 2021; 182(4):339-349. PubMed ID: 33524979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronavirus vaccine development: from SARS and MERS to COVID-19.
    Li YD; Chi WY; Su JH; Ferrall L; Hung CF; Wu TC
    J Biomed Sci; 2020 Dec; 27(1):104. PubMed ID: 33341119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 Vaccines: Should We Fear ADE?
    Halstead SB; Katzelnick L
    J Infect Dis; 2020 Nov; 222(12):1946-1950. PubMed ID: 32785649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2.
    Tostanoski LH; Gralinski LE; Martinez DR; Schaefer A; Mahrokhian SH; Li Z; Nampanya F; Wan H; Yu J; Chang A; Liu J; McMahan K; Ventura JD; Dinnon KH; Leist SR; Baric RS; Barouch DH
    J Virol; 2021 Nov; 95(23):e0097421. PubMed ID: 34523968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanocarrier vaccines for SARS-CoV-2.
    Machhi J; Shahjin F; Das S; Patel M; Abdelmoaty MM; Cohen JD; Singh PA; Baldi A; Bajwa N; Kumar R; Vora LK; Patel TA; Oleynikov MD; Soni D; Yeapuri P; Mukadam I; Chakraborty R; Saksena CG; Herskovitz J; Hasan M; Oupicky D; Das S; Donnelly RF; Hettie KS; Chang L; Gendelman HE; Kevadiya BD
    Adv Drug Deliv Rev; 2021 Apr; 171():215-239. PubMed ID: 33428995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.